Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study. This is an ASCO Meeting Abstract from the ...

Advantages of minimally invasive surgery for remnant gastric cancer: A multi-institutional cohort study. This is an ASCO Meeting Abstract from the 2023 ASCO Gastrointestinal Cancers Symposium. This ...

Mode of detection of second breast cancers in patients undergoing surveillance after treatment of ductal carcinoma in situ. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This ...

Evolving treatment landscape in metastatic urothelial carcinoma (mUC) post-avelumab maintenance approval: Real-world insights from The US Oncology Network.

RAGE inhibition to decrease cancer therapy related cardiotoxicity in women with early breast cancer (RAGE). This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not ...

Genomic correlates of acquired resistance to PD-(L)1 blockade in patients with advanced non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This ...

A randomized controlled trial comparing primary tumor resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group study JCOG1017.

CASPAR (Alliance A031902): A randomized, phase III trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) as a novel therapy in first-line metastatic castration-resistant prostate cancer ...

Evaluation of real-world cost savings and utilization of biosimilar drugs in a community-based oncology practice. This is an ASCO Meeting Abstract from the 2021 ASCO Quality Care Symposium. This ...

Final survival analysis of the phase III OVHIPEC-1 trial of hyperthermic intraperitoneal chemotherapy in ovarian cancer after ten year follow-up. Randomized phase 2 study of gemcitabine with or ...

Safety and efficacy of ifebemtinib (IN10018) combined with garsorasib (D-1553) in KRAS G12C mutant solid tumors from a phase Ib/II study: Results from single-arm of non-small-cell lung cancer (NSCLC) ...

Pointed Progress in Second-Line Advanced Non–Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition Two trials investigating the addition of ovarian suppression to tamoxifen did ...